Sutro Biopharma(STRO)
SOUTH SAN FRANCISCO, CA
Pharmaceutical4 H-1B visas (FY2023)Focus: Biochemical Protein Synthesis Platform
Sutro Biopharma is a life sciences company focused on Biochemical Protein Synthesis Platform.
Oncology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
STRO-002
Ovarian CancerClinical Trials (1)
NCT05200364A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Phase 1STRO-002
Ovarian CancerClinical Trials (1)
NCT03748186Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1STRO-001
B-cell LymphomaClinical Trials (1)
NCT03424603Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Phase 1Phase 1
Clinical Trials (1)
NCT07227168A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Phase 1STRO-002
Neoplasm MalignantClinical Trials (1)
NCT06238687A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Phase 1/2Luveltamab tazevibulin
Acute Myeloid Leukemia (AML)Clinical Trials (1)
NCT06679582Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Phase 1/2Luveltamab tazevibulin
Lung CancerClinical Trials (1)
NCT06555263Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Luveltamab tazevibulin
Ovarian CancerClinical Trials (1)
NCT05870748REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Phase 2/3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 8 clinical trials
H-1B (2023): 4 approvals
SEC Filings: 2 available
Financials (FY2024)
Revenue
$68M10%
R&D Spend
$137M(202%)31%
Net Income
-$119MCash
$47MHiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 2 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
4
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub